Blog
RSS FeedPosted by Michael Wonder on 04 Aug 2022
Advanced oesophageal carcinoma: nivolumab in combination with chemotherapy or ipilimumab prolongs life compared to chemotherapy alone
1 August 2022 - The additional clinical benefit cannot be quantified because the data on health status and health-related quality ...
Posted by Michael Wonder on 19 Jul 2022
German Government announces bill to drastically slash drug reimbursement
19 July 2022 - On 8 July 2022, the German Health Ministry has officially shared the second edition of a new ...
Posted by Michael Wonder on 02 Jun 2022
Post-menopausal osteoporosis: advantages of teriparatide over risedronate sodium
2 June 2022 - Preliminary report on the comparative benefit assessment of bisphosphonates, teriparatide and denosumab is available. Please submit ...
Posted by Michael Wonder on 29 May 2022
Application accompanying data collection in the case of market access for several active substances in a class: IQWiG presents a concept
27 May 2022 - The institute recommends platform studies under a master's protocol. ...
Posted by Michael Wonder on 19 May 2022
G-BA certifies active ingredients against breast and oesophageal cancer as having a high additional benefit
19 May 2022 - The Federal Joint Committee (G-BA) has rated the patient-relevant additional benefit of two active ingredients for cancer ...
Posted by Michael Wonder on 04 May 2022
Methods paper: new version 6.1 becomes effective – English translation now available
2 May 2022 - The amendments concern, among other things, the approach to evidence searches for clinical practice guidelines. New ...
Posted by Michael Wonder on 19 Apr 2022
Supply related data in manufacturer dossiers: things are not going smoothly yet
19 April 2022 - The criteria for supply related data established by IQWiG in 2020 were positively received in science. ...
Posted by Michael Wonder on 19 Apr 2022
Lenvatinib and pembrolizumab in endometrial cancer: patients live significantly longer
19 April 2022 - There is an indication of a considerable added benefit compared to doxorubicin or paclitaxel. Compared to ...
Posted by Michael Wonder on 12 Apr 2022
Prospective measures to combat rising drug prices in Germany
13 April 2022 - This article provides an overview of potential tools being explored in Germany by Health Insurance Funds to ...
Posted by Michael Wonder on 24 Mar 2022
Despite competition, U.S. cancer drug prices rose even as they fell in Germany and Switzerland
24 March 2022 - Even as prices rose substantially in the U.S. over a recent 12 year period, a new ...
Posted by Michael Wonder on 15 Mar 2022
Hansa Biopharma and German payer head association agree on reimbursement price for Idefirix (imlifidase) as desensitisation treatment for highly sensitised kidney transplant patients
15 March 2022 - Hansa Biopharma completes the AMNOG reimbursement process for Idefirix in Germany. ...
Posted by Michael Wonder on 03 Mar 2022
Criticism of study planning: patient-reported endpoints are often collected far too briefly
3 March 2022 - A striking example: abemaciclib in advanced breast cancer. Shortened data on quality of life, symptoms and side ...
Posted by Michael Wonder on 01 Mar 2022
Triple negative breast cancer: survival benefit with sacituzumab govitecan
1 March 2022 - Those affected survive a median of twelve months compared to seven in the control group. Overall, ...
Posted by Michael Wonder on 15 Feb 2022
Pembrolizumab in combination with chemotherapy: significant additional benefit in advanced squamous cell carcinoma of the oesophagus
15 February 2022 - Those affected survived a median of 14 months compared to nine in the control group. However, an ...
Posted by Michael Wonder on 02 Feb 2022
Register study on gene therapy with Zolgensma starts
1 February 2022 - Experience from clinical practice with Zolgensma, a gene therapy against certain forms of spinal muscular atrophy in ...